Companies: 10,795·Total market cap: $144.5T

Altamira Therapeutics Ltd.

Altamira Therapeutics Ltd.

CYTONASDAQHealthcare

$0.30

+$0.30(+100.00%)

Market Cap$1133556

P/E Ratio—

52W High$0.4158

52W Low$0.3

Avg Volume244K

Open$0.30

Beta2.44

Net Income Financials Revenue

Altamira Therapeutics Ltd. (CYTO) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

CYTO · net income · updated Jun 9, 2026

Core profitability metrics

CYTO · net income · margin · TTM · CAGR

Net income was −$7.3M for FY2023 (fiscal year ending 2023-12-31), up 72.6% year-over-year. Net profit margin was —.

FY2023 Net Income−$7.3M▲ +72.6% YoY

Trailing 12M (TTM)—trailing 4 quarters sum

Net Profit Margin——

YoY Change+72.6%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · CYTO net income history · CYTO profit margin

Annual net income data

CYTO · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2023Loss−$7.3M▲ +72.6%—$0

FY2022Loss−$26.5M▼ 55.5%-8680.2%$305,616

FY2021Loss−$17.1M▼ 108.0%-26703.0%$63,882

FY2020Loss−$8.2M▼ 23.6%-4699.8%$174,475

FY2019Loss−$6.6M▲ +42.3%—−$56,000

Net income vs peers (Healthcare)

CYTO vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Altamira Therapeutics Ltd. (CYTO) reported net income of −$7.3M for FY2023 (fiscal year ending 2023-12-31), up 72.6% year-over-year. The net profit margin was — — meaning the company kept $— of every dollar of revenue as profit.

Altamira Therapeutics Ltd. has not yet achieved annual profitability based on available data (12 fiscal years). The company has reported net losses across all available periods.

Altamira Therapeutics Ltd.'s net profit margin was — for FY2023, based on the latest annual results.

Investors sometimes search for "Altamira Therapeutics Ltd. net worth" — the company's market capitalization is a separate figure from CYTO net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

CYTO net income · 4 questions

Altamira Therapeutics Ltd. is not currently profitable on an annual basis. The company reported a net loss of $7.3M for FY2023.

is CYTO profitabledoes CYTO make a profitCYTO profitabilityCYTO profitable company

▸ Source: FMP /income-statement · GAAP · Altamira Therapeutics Ltd. · Altamira Therapeutics Ltd. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026